Gain Therapeutics terminates at-the-market offering agreement with Cantor Fitzgerald

Gain Therapeutics, Inc.

Terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald effective Nov 13, 2023.
Agreement allowed for at-the-market sales; 865,535 shares sold for net proceeds of $3.5M total.
Company gave immediate notice; no reason for termination provided in the filing.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Gain Therapeutics, Inc. terminated Sales Agreement with Cantor Fitzgerald & Co. (effective 2023-11-13).

Action: termination
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Effective: 2023-11-13

Exact text from the filing

On November 13, 2023, Gain Therapeutics, Inc. (the “ Company ”) notified Cantor Fitzgerald & Co. (“ Cantor ”) of its decision to terminate the Controlled Equity Offering SM Sales Agreement, dated as of May 18, 2022, (the “ Sales Agreement ”) between the Company and Cantor, effective immediately (the “ Termination Date ”).

View on SEC.gov

629 material agreements filed in the last 30 days. Browse all material agreements →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-119532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.